Application of fluoroquinolone pharmacodynamics

Journal of Antimicrobial Chemotherapy

Volumn 46, Issue 5, 2000, Pages 669-683

  Wright, David H ^a,b   Brown, Gigi H ^a,b   Peterson, Marnie L ^a,b   Rotschafer, John C ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b REGIONS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALATROFLOXACIN; ALMITIL; AMINOGLYCOSIDE; CHIBROXOL; CHIMONO; CINOXACIN; CIPROFLOXACIN; CLINAFLOXACIN; ENOXACIN; ENOXOR; FULGRAM; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; NETILMICIN; NORFLOXACIN; OFLOXACIN; OXOLINIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; SPARFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG; ZEGAM;

ANAEROBIC BACTERIUM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BINDING; GRAM NEGATIVE BACTERIUM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PROTEIN BINDING; RAT; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT INFECTION;

ANIMALS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BACTERIA, ANAEROBIC; CLINICAL TRIALS; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PNEUMOCOCCAL INFECTIONS; SPECIES SPECIFICITY;

EID: 0033736932     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/46.5.669     Document Type: Review

References (75)

1. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
2. Kinetics of antimicrobial activity
3. Pharmacodynamic properties of antibiotics: Application to drug monitoring and dosage regimen design
4. Dosis-Wirkungs-Beziehung der Bakterizidie bei E. Coli, K. Pneumoniae und Staphylococcus aureus
5. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
6. Mathematical examination of dual individualization principles: I. Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin
7. Pharmacokinetic and microbiologic evaluation of dosage regiments for newer cephalosporins and penicillins
8. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration
9. Time course of the pharmacological response to β-lactam antibiotics in vitro and in vivo
10. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication
11. Benemid, p-(di-n-propylsulfamyl)-benzoic acid: Its renal affinity and its elimination
12. Pharmacodynamic interactions of antibiotics alone and in combination
13. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract
14. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones'
15. Resistance surveillance of Streptococcus pnuemoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998
16. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong
17. New uses for new and old quinolones and the challenge of resistance
18. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
19. Pharmacodynamics of fluoroquinolones
20. Community-acquired pneumonia in adults: Guidelines for management
21. Commentary on the 1993 American Thoracic Society guidelines for the treatment of community-acquired pneumonia
22. Community-acquired pneumonia
23. Correlation of pharmacokinetic parameters to efficacy of antibiotics: Relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia
24. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance
25. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: Effect of simultaneous versus staggered administration in an in vitro model of infection
26. Twenty-four hour area under the concentration-time curve/MIC ratio as a generic predictor of predictor of fluoroquinolone antimicrobial effect using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model
27. Inter- and intraquinlone predictors of antimicrobial effect in an in vitro dynamic model: New insight into a widely used concept
28. MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model
29. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: Action of ciprofloxacin against Escherichia coli in an in vitro dynamic model
30. A new approach to in-vitro comparisons of antibiotics in dynamic models: Equivalent AUC/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibility
31. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model
32. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
33. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model
34. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model
35. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model
36. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models
37. Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model
38. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis
39. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
40. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar
41. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis
42. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patient during therapy
43. Effect of aerobic and anaerobic environments on antistaphylococcal activities of five fluoroquinolones
44. Comparison of agar dilution, microdilution, E-test, and disk diffusion methods for testing activity of cefditoren against Streptococcus pneumoniae
45. Anti-pneumococcal activities of levofloxacin and clarithromycin as determined by agar dilution, microdilution, E-test, and disk diffusion methodologies
46. Susceptibility testing of Klebsiella spp.-an international collaborative study in quality assessment
47. Antibiotic susceptibility testing (agar disk diffusion and agar dilution) of clinical isolates of Enterococcus faecalis and E. Faecium: Comparison of Mueller-Hinton, Iso-Sensitest, and Wilkins-Chalgren agar media
48. Problems arising in antimicrobial therapy due to false susceptibility testing
49. Muliticenter evaluations of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131, 628, compared with the activity of ciprofloxacin against 5, 252 clinical bacterial isolates
50. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains
51. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parEloci
52. Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections
53. The activity of grepafloxacin against respiratory pathogens in the UK